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A B S T R A C T
Since the advent of kidney transplantation a key strategy for maximising graft survival by avoiding allor-
ecognition has been to minimise HLA mismatching between donor and recipient. As HLA antibodies are now
recognised as being speciﬁc for epitopes and donor-recipient HLA mismatch at the amino acid level can now be
determined, HLA epitope mismatch load could be a better predictor for dnDSA development than classical HLA
antigen mismatch calculation. This hypothesis has been investigated by other studies and the aim of our mul-
ticentre study was to conﬁrm this observation in our population. Two algorithms, HLAMatchmaker and PIRCHE-
II, were used to determine the HLA epitope mismatch load between donor and recipient. We have shown a
signiﬁcant association between the number of HLA epitope mismatches and the development of dnDSA and we
have conﬁrmed the earlier observations.
1. Introduction
Kidney transplantation is the treatment of choice for most patients
suﬀering from end-stage renal disease (ESRD). HLA disparity between
donor and recipient aﬀects transplant immunity and consequently has
an impact on graft outcome. One of the alloimmune mechanisms is the
development of de novo donor speciﬁc antibodies (dnDSA), which re-
presents a risk factor for humoral transplant rejection. This antibody-
mediated rejection (ABMR) is a major cause of premature graft loss in
kidney transplantation [1].
Currently, the Eurotransplant Kidney Allocation System (ETKAS) is
based on HLA-A, -B broad and HLA-DR split antigen matching.
Transplants with zero HLA-A, -B and -DR mismatches have superior
outcomes compared with outcomes for grafts with one or more HLA
mismatches. Nevertheless, a signiﬁcant proportion of these transplants
fail prematurely, possibly reﬂecting potential allorecognition of donor
incompatibilities. This may be due to diﬀerent alleles of HLA-A, -B and
-DR loci or diﬀerences in antigens at other loci, such as HLA-C, -DQ and
-DP. On the other hand, many HLA-mismatched grafts have excellent
graft outcomes, suggesting that certain HLA mismatches may be per-
missible [2].
Another model of matching, considering cross-reacting groups
(CREGs), may increase the probability of identifying more compatible
kidneys. HLA antigens comprise multiple epitopes made of polymorphic
amino acid residues and it is these structures and their conformation
that determine antibody accessibility, recognition, and subsequent re-
activity. CREGs share one or more epitopes and immunisation against
an HLA antigen often results in antibodies that bind not only to the
immunising antigens, but also to sets of structurally similar antigens.
However, the true eﬃcacy of CREG matching in cadaveric kidney
transplantation is controversial [2,3].
Current methods using single antigen bead assays for “high resolu-
tion” antibody detection in combination with high resolution typing (or
intermediate interpretation of low resolution data) allow better iden-
tiﬁcation of B cell epitopes, initially based upon serologic cross-re-
activity patterns (CREGs). A computer algorithm HLAMatchmaker de-
veloped by R. Duquesnoy deﬁnes the number and B cell functional
epitope mismatches between donor and recipient, the so-called mis-
matched eplets or parts of the B cell epitopes that trigger an antibody
response. It regards each mismatched HLA antigen as a three-dimen-
sional structure of polymorphic amino acid conﬁgurations in antibody-
accessible positions and the mismatches are determined by the
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recipient's HLA type, representing a repertoire of self-epitopes for which
no antibodies can be made. It has been shown by several cohort studies
that the number of eplet mismatches is associated with the development
of dnDSA and premature graft loss [4].
Besides B cell epitopes, T cell epitopes may also play a role in an-
tibody formation. DSA production occurs via the indirect allorecogni-
tion pathway in which foreign HLA is processed by the recipient's an-
tigen-presenting cells and presented by HLA class II to CD4+ T cells,
followed by B cell activation with antibody production. As such, HLA-
derived T-cell epitopes, designated as PIRCHE-II (Predicted Indirectly
ReCognizable HLA Epitopes presented by HLA class II molecules), also
play a role in the generation of DSA. The group led by E. Spierings has
shown that the PIRCHE-II score predicts the incidence of dnDSA and
graft failure after kidney transplantation [5,6,7].
The aim of our multicentre study was to perform an independent
conﬁrmation of earlier observations that HLAMatchmaker and PIRCHE-
II scores may be a better predictor for dnDSA formation than classical
HLA antigen matching.
Here, we compared conventional HLA antigen mismatch assess-
ment, with the algorithms HLAMatchmaker (www.epitopes.net) and
PIRCHE-II (www.pirche.org) to predict dnDSA development [5,6,7,8].
2. Materials and methods
2.1. Patient population
This study was performed in the HLA laboratory of Red Cross
Flanders (Histocompatibility and Immunogenetics Laboratory (HILA),
Mechelen, Belgium). This is the only EFI accredited HLA laboratory in
Flanders for organ transplantation and provides services for the kidney
transplantation centres of the Antwerp University Hospital, the Ghent
University Hospital and the University Hospitals Leuven.
We only included kidney transplant patients who were on the
Eurotransplant list waiting for a second transplantation, and who had
Luminex antibody testing performed in 2017. We speciﬁcally selected
retransplant candidates, regardless of the cause of previous graft
failure. Many retransplant candidates have HLA antibodies when back
on the waiting list for a second graft, and these antibodies originate
from HLA mismatching with the ﬁrst kidney donor. This cohort selec-
tion increases the power of the analyses, because assessing the asso-
ciation between HLA mismatches and de novo antibody occurrence
after transplantation in a cohort with ﬁrst transplantations would lack
power and require a very large data set.
We only included patients without pre-existing HLA antibodies prior
to the ﬁrst graft and who had complete HLA typing (HLA-A,-B,-C,-DR,-
DQ) available for both the patient and the ﬁrst kidney donor (35 de-
ceased donors and 1 living related donor). Patients were transplanted
between 1985 and 2016. Before 2008 pre-transplant screening was not
performed with Luminex technology but with CDC (Complement-
Dependent Cytotoxicity, 14 patients) or Enzyme-Linked-
Immunosorbent assay (ELISA, 3 patients). Admittedly, CDC and ELISA
are less sensitive than the Luminex Single Antigen test in detecting
dnDSA. As CDC screening has a very low sensitivity, only men (12
patients), and women (2 patients) without a history of pregnancy, were
included. A total of 36 patients were enrolled in the study (Table 1).
Twenty-six patients (72%) developed dnDSA. For 33 patients DSA de-
tection was performed at least 6 months after graft loss.
2.2. HLA genotyping and antibody testing
HLA-A,B,C,DR,DQB1 genotyping was performed with Immucor
LIFECODES® HLA-SSO (sequence-speciﬁc oligonucleotides, inter-
mediate resolution) or Olerup® HLA-SSP (sequence-speciﬁc primers,
low resolution) kits. We used EpViX (www.epvix.com.br, version 2.4)
to convert low resolution HLA typing (HLA-SSP) into the most likely
high-resolution typing, based on common associations of HLA-B-C and
HLA-DR-DQ and population frequency databases from NMDP and
IMGT. HLA antibody evaluation of all patient samples was performed
with Immucor LIFECODES® LifeScreen Deluxe kits. A positive screening
for the presence of circulating HLA antibodies was followed by HLA
antibody identiﬁcation with LIFECODES® LSA (Luminex Single
Antigen) kits. All tests were performed and interpreted according to the
manufacturer's instructions. All serum samples were treated with EDTA
to eliminate the prozone eﬀect.
2.3. HLAMatchmaker and PIRCHE-II analysis
We used HLAMatchmaker version 02 [8] to determine the number
of non-self-B-cell-functional-epitope mismatches against the back-
ground of self-epitopes, and thus to calculate the number of eplet
mismatches or the HLAMatchmaker score. The PIRCHE-II algorithm
version 2.5 [6] was used to count the number of mismatched HLA-de-
rived epitopes that are involved in indirect T cell alloimmune responses
and that are predicted to be presented in the peptide binding groove of
HLA class II molecules, and thus to calculate the T cell epitope mis-
match load or PIRCHE-II score.
2.4. Statistics
The relationship between dnDSA and HLA mismatch load (HLA-
A,B,DR split antigen mismatch load; HLA-A,B,C,DR,DQ split antigen
mismatch load; HLAMatchmaker score; and PIRCHE-II score) was in-
vestigated using logistic regression analysis. Groups were compared
using unpaired t tests. Data are presented as median and range or
percentage, as appropriate. All analyses were performed with GraphPad
Prism version 7.00, GraphPad Software, La Jolla California USA, www.
graphpad.com.
3. Results
The study cohort comprised 36 renal transplant patients with a
median age of 39 (range 4–71) at the time of their ﬁrst transplant.
Seventy-two percent of patients (N=26) developed dnDSA after the
ﬁrst transplant with anti-HLA-DQ as the predominant dnDSA (N=21,
81%). Recipients received a transplant with a median cumulative A-B-
DR mismatch of 3 (range 0–6) and A-B-C-DR-DQ mismatch of 5 (range
0–10). HLAMatchmaker scores ranged from 0 to 62 for the overall co-
hort with a median of 28. PIRCHE-II scores ranged from 0 to 130 with a
median of 48. Patient cohort characteristics and parameters are sum-
marised in Table 1.
Fig. 1 shows the correlation of the number of HLA antigen mis-
matches, HLAMatchmaker and PIRCHE-II scores with the detection of
dnDSA. The eﬀect of HLA-A,B,DR antigen mismatch load was
Table 1
Patient characteristics (N=36).
Parameter Median (range or
percentage)
Age at time of ﬁrst transplant 39 (4–71)
Female gender 13 (36%)
HLA antibody positivity prior to the ﬁrst
transplantation
0 (0%)
Time between transplantation and graft loss
(years)
4 (0.01–24)
De novo DSA positivity, N (%) 26 (72%)
HLA class I, N (%) 15 (58%)
HLA class II, N (%) 24 (92%)
HLA class I+ II, N (%) 13 (50%)
HLA-DQ, N (%) 21 (81%)
HLA antigen mismatches (A-B-DR) 3 (0–6)
HLA antigen mismatches (A-B-C-DR-DQ) 5 (0−10)
HLAMatchmaker score 28 (0–62)
PIRCHE-II score 48 (0−130)
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signiﬁcant (AUC=0.73, P=0.01), but improved when HLA-C and
HLA-DQ mismatch were added (AUC=0.78, P= 0.003). PIRCHE-II
scores (AUC=0.80, P=0.003) and HLAMatchmaker scores were the
best predictors of dnDSA (AUC=0.85, P=0.003).
Given the dominance of anti-HLA-DQ antibodies in the de novo
occurrence of HLA antibodies, we then focused on mismatches in the
HLA-DQ locus. In this study no anti-HLA-DQA1 antibodies without anti-
HLA-DQB1 DSA were detected. A wide variation in HLA-DQB1
HLAMatchmaker and PIRCHE-II scores were observed for the corre-
sponding antigen mismatch (Fig. 2a). Fig. 2b shows the correlation of
Fig. 1. Correlation of the number of classical HLA antigen (Ag) mismatches (MM), HLAMatchmaker and PIRCHE-II scores with dnDSA.
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HLA-DQB1 HLAMatchmaker and PIRCHE-II scores with the detection of
de novo anti-HLA-DQ DSA. When the HLA-DQB1 HLAMatchmaker
score was below 6, no de novo HLA-DQ antibodies were detected. In
84% of patients with an HLA-DQB1 mismatch load ≥6, de novo HLA-
DQ DSA were present. As shown in Fig. 2a no upper limit could be
deﬁned; even up to an HLAMatchmaker score of 19 no dnDSA were
observed.
For PIRCHE-II a stratiﬁcation into low or high scores based on the
ﬁrst quartile and the third quartile of the HLA-DQB1 PIRCHE-II score
could be performed. Below the ﬁrst quartile de novo anti-HLA-DQ DSA
was 0% and above the third quartile 100% in the group with one HLA-
DQB1 antigen mismatch as shown in Fig. 2a.
4. Discussion
In this study, we described a signiﬁcant association between the
number of HLA epitope mismatches and the development of dnDSA. We
showed that the epitope mismatch load was a better predictor than the
classical HLA antigen mismatch calculation. HLA epitope mismatch
assessment enhances the precision by quantifying the degree of simi-
larity between donor/recipient HLA at the molecular level [9,10,11].
Because the majority of dnDSA in our study are anti-HLA-DQ anti-
bodies and because DSAs directed against HLA-DQ are more frequently
associated with antibody-mediated rejection and portend a poorer
prognosis than DSAs against HLA class I [12,13], we also focused on the
HLA-DQB1-speciﬁc epitope mismatch load. The number of these epi-
tope mismatches was indeed highly predictive of HLA-DQ dnDSA
Fig. 2. Association between HLA-DQ mismatch and de novo anti-HLA-DQ antibodies.
2.a A wide variation in HLA-DQB1 HLAMatchmaker and PIRCHE-II scores for the corresponding antigen mismatch.
2.b Correlation of HLAMatchmaker and PIRCHE-II scores with de novo anti-HLA-DQ DSA.
L. Daniëls et al. Transplant Immunology xxx (xxxx) xxx–xxx
4
development post-transplant. We also conﬁrmed, as shown in Fig. 2a,
the observation of Lachman et al. [5] that the strongest impact of the
PIRCHE-II score on diﬀerentiation into low- and elevated risk patients
could be revealed for patients with one HLA-DQB1 mismatch.
Together with other studies illustrating the potential value of more
detailed HLA mismatch analysis in kidney transplantation
[4,5,7,9,10,11,12], our data suggest that the number of HLA epitope
mismatches can be used as a risk assessment tool at time of trans-
plantation and for post-transplantation follow-up, to evaluate those
patients at the highest risk of HLA antibody formation. This could be
especially valuable in young and paediatric kidney recipients, who will
probably need more than one kidney allograft in their lifetime.
Although our study suggests that the total epitope mismatch load
could be the determining factor in the risk of HLA antibody formation,
it is clear that we lack data on the immunogenicity of the epitope
mismatches. It could be that immunogenicity is not merely a quanti-
tative issue, but that one or only a few epitope mismatches are suﬃ-
cient to induce an antibody response. Maybe, the higher number of
epitope mismatches only enhances the chance to include im-
munodominant epitopes [3]. High resolution level analysis of the an-
tibody response is therefore required to further unravel the im-
munogenicity of epitopes in a given donor/recipient combination as
well as a more detailed deﬁnition of the epitope mismatches. Although
not analysed in this study, information on the ethnic background of
patients versus donors is important when analysing epitopes and we
acknowledge that this is a limitation of the study. It is known that in-
dividuals from diﬀerent ethnic backgrounds, although having identical
HLA antigens, can have a high prevalence of speciﬁc alleles that can be
absent in other populations [4].
The strong association between the HLAMatchmaker and PIRCHE-II
scores and the risk of dnDSA formation was observed despite the im-
portant heterogeneity in centre practice (e.g. of immunosuppression
withdrawal and transplant nephrectomy), causes of graft failure and
timing of the HLA antibody evaluation. This suggests that the HLA
mismatch scores are indeed more important than the clinical inter-
vention after graft loss in the development of dnDSA. Our limited study
size does not allow this to be conﬁrmed in multivariable analyses, and
future research is warranted to evaluate the relative contribution of
HLA mismatch scores and clinical interventions (transplant ne-
phrectomy, immunosuppression withdrawal, etc.) to dnDSA formation.
In conclusion, we independently conﬁrm earlier observations that
HLAMatchmaker and PIRCHE-II scores are a better predictor for dnDSA
formation after kidney transplantation than classical antigen mismatch
analysis.
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